Xiaoni Liu

发表

Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

S. Griffen, F. LaCreta, D. Boulton, 2013, Clinical Pharmacokinetics.

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

R. DeFronzo, S. Griffen, F. LaCreta, 2013, Diabetes Care.

of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

R. DeFronzo, S. Griffen, F. LaCreta, 2013 .

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

W. Humphreys, F. LaCreta, D. Boulton, 2013, British journal of clinical pharmacology.

Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.

S. Griffen, F. LaCreta, D. Boulton, 2015, Clinical therapeutics.

Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin

S. Griffen, F. LaCreta, D. Boulton, 2012, Advances in Therapy.

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects

Sun Ku Lee, Rong Shi, D. Shevell, 2016, Journal of clinical pharmacology.

Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets.

R. Tejwani, S. Griffen, F. LaCreta, 2016, International journal of pharmaceutics.

Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: An observation study in Chinese patients

Xiang Li, Xiaoni Liu, Hai-Jin Yu, 2019, Journal of Neuroimmunology.

Optimal encephalitis/meningitis roadmap via precise diagnosis and treatment (IMPROVE): a study protocol for a randomized controlled trial

Wenhong Zhang, Shengjian Lu, Xiaoni Liu, 2022, BMC Infectious Diseases.

HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients

Yuehua Gu, Shuizhen Zhou, Wenhui Li, 2019, Journal of Clinical Neuroscience.

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

F. LaCreta, D. Boulton, M. Pfister, 2011, Clinical therapeutics.

Hydrogen Sulfide Regulates the [Ca2+]i Level in the Primary Medullary Neurons

N. Zhang, Rui Wang, Ying Huang, 2016, Oxidative medicine and cellular longevity.

Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.

S. Griffen, F. LaCreta, D. Boulton, 2013, Clinical therapeutics.

Is low threshold of B cells an obligatory monitoring indicator of repeated RTX infusion in the treatment of Neuromyelitis Optica spectrum disorder? – A report of two cases

Xiaoni Liu, Lijun Jing, Hai-Jin Yu, 2021, Neuroimmunology Reports.

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

S. Griffen, F. LaCreta, D. Boulton, 2011, Diabetes, obesity & metabolism.

Superoxide Mediates Depressive Effects Induced by Hydrogen Sulfide in Rostral Ventrolateral Medulla of Spontaneously Hypertensive Rats

Haiyan Xu, N. Zhang, Jerry Yu, 2015, Oxidative medicine and cellular longevity.

Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

F. LaCreta, D. Boulton, M. Pfister, 2011, Diabetes, obesity & metabolism.